All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news

RSS

← First12345...717Next →

hiv & aids news selected from other sources

  • Sex workers
    HIV stigma drives sex work in Northern Kenya
    Key Correspondents | 9 hours ago

    When Zeinab left her home village in Northern Kenya to look for a job, she had one thing in mind; work hard to help her struggling family. But her plans were destroyed by something that would keep her from home for the rest of her life.

  • PrEP
    UNAIDS welcomes further evidence of the efficacy of antiretroviral medicines in preventing new HIV infections
    UNAIDS | 9 hours ago

    UNAIDS strongly welcomes results from scientific trials presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI), held in Seattle, United States of America.

  • Starting treatment
    Inflammation Persists Despite Very Early HIV Treatment
    The Body Pro | 9 hours ago

    Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy, according to a study presented at CROI 2015, in Seattle, Washington.

  • Pharmaceutical industry
    Gilead avoids billions in U.S. taxes on its $1,000-a-pill drug
    Chicago Tribune | 14 hours ago

    Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas.

  • HIV prevention policy
    HIV Prevention Cuts Medical Costs
    MedPage Today HIV/AIDS | 14 hours ago

    Averting a single infection could save up to $338,000 over a lifetime.

  • PrEP
    HIV pill: The logic of paying £500 a month so gay men don't have to wear condoms
    The Independent | 26 February 2015

    At a time when the NHS is under immense financial strain – some might say bankrupt – it may seem odd to suggest that the health service pay nearly £500 a month for a gay man to take a daily pill so that he doesn’t have to wear a condom. However, the scientists behind this clinical trial believe that a policy of offering daily drugs aimed at curbing new HIV infections within certain high-risk groups of men who have sex with men may actually save the NHS money in the long term.

  • TB services
    CROI 2015: Trial to evaluate the use of health navigators to link HIV/TB patients to care and treatment fails to show positive results
    Science Speaks | 26 February 2015

    Patients randomized to the support of a health navigator were not more likely than those who received standard of care to complete tuberculosis treatment or begin antiretroviral therapy within three months of HIV diagnosis, according to the results of a South African randomized trial presented here today.

  • Hepatitis C treatment
    NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C
    NICE press release | 26 February 2015

    Following a request from NHS England and consultation with stakeholders, the period during which NHS England has to comply with the recommendations for sofosbuvir is extended to 31 July 2015. The period during which NHS England has to comply with the recommendations for simeprevir has not been extended.

  • New and experimental hepatitis C treatment
    New hepatitis C treatments highly effective for HIV/HCV coinfected people
    HIVandHepatitis.com | 26 February 2015

    A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

  • New and experimental HIV treatments
    48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation
    Bristol Myers Squibb press release | 26 February 2015

    Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients. Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells. Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells PRINCETON, N.J., February 25, 2015--Bristol-Myers Squibb Company (NYSE:BMY) today announced data...

← First12345...1014Next →

Hepatitis C news

WHO recommends global use of newest hepatitis C drugs, urges price reductions.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Treatment as prevention

No-one with an undetectable viral load, gay or heterosexual, transmits HIV in two years of PARTNER study.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.